Unadjusted analysis | Adjusted analysis* | |||
---|---|---|---|---|
Variable | HR (95% CI) | p Value | HR (95% CI) | p Value |
Sex | ||||
Female | 1.000 | |||
Male | 1.266 (1.060 to 1.511) | 0.009 | ||
Age at onset (year) | 1.039 (1.031 to 1.046) | <0.001 | ||
BMI (kg/m2) | 0.958 (0.925 to 0.992) | 0.016 | 0.959 (0.925 to 0.994) | 0.021 |
Diagnostic delay from symptom onset (months) | 0.953 (0.946 to 0.959) | <0.001 | 0.950 (0.943 to 0.957) | <0.001 |
Phenotype | ||||
Limb-onset ALS | 1.000 | 1.000 | ||
Bulbar-onset ALS | 1.531 (1.220 to 1.921) | <0.001 | 1.323 (1.050 to 1.667) | 0.017 |
FAS | 0.787 (0.576 to 1.075) | 0.132 | 0.578 (0.420 to 0.795) | 0.001 |
PMA | 0.794 (0.466 to 1.353) | 0.396 | 0.795 (0.466 to 1.358) | 0.402 |
PLS | 0.000 (0.000 to 1.709E81) | 0.913 | 0.000 (0.000 to 1.139E84) | 0.914 |
Airlie House category | ||||
Clinically definite | 1.000 | 1.000 | ||
Clinically probable | 0.943 (0.745 to 1.195) | 0.629 | 0.861 (0.679 to 1.091) | 0.216 |
Laboratory-supported probable | 0.624 (0.440 to 0.885) | 0.008 | 0.567 (0.400 to 0.805) | 0.001 |
Clinically possible | 0.821 (0.641 to 1.053) | 0.120 | 0.687 (0.535 to 0.884) | 0.003 |
Suspected | 0.740 (0.467 to 1.171) | 0.199 | 0.714 (0.449 to 1.136) | 0.156 |
Place of residence | ||||
Urban | 1.000 | 1.000 | ||
Rural | 1.202 (1.010 to 1.431) | 0.039 | 1.436 (1.202 to 1.716) | <0.001 |
Other factors that did not reach statistical significance in the analysis are not shown in the table.
*The analysis is adjusted for age at onset and sex.
ALS, amyotrophic lateral sclerosis; BMI, body mass index; FAS, flail arm syndrome; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy.